Aerie Pharmaceuticals Incの売上総利益
Aerie Pharmaceuticals Incの売上総利益 は何ですか。
Aerie Pharmaceuticals Incの売上総利益 は89.01%です。
売上総利益 の定義は何ですか。
売上総利益は、売上と商品の売上原価との差を収益で除してパーセンテージで表したものです。
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
NASDAQのセクタHealth Careにおける売上総利益 の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の売上総利益
- Cohen & Steersの売上総利益 は88.94%です。
- MCAN Mortgageの売上総利益 は88.95%です。
- Pendragon Plcの売上総利益 は88.98%です。
- Lifull Coの売上総利益 は88.98%です。
- Memphasysの売上総利益 は88.99%です。
- Modivの売上総利益 は89.00%です。
- Aerie Pharmaceuticals Incの売上総利益 は89.01%です。
- Odyssey Technologiesの売上総利益 は89.04%です。
- Invesco QQQ Trust, Series 1の売上総利益 は89.04%です。
- IntelliCentrics Globalの売上総利益 は89.06%です。
- Adlabs Entertainmentの売上総利益 は89.09%です。
- Resimac Ltdの売上総利益 は89.09%です。
- Indo Thai Securitiesの売上総利益 は89.12%です。